CEACAM5 and breast carcinoma: By monitoring a series of liquid biopsy biomarkers including serum levels of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA), the CTC/CTM of patients with breast cancer during their follow-up visits, the state of disease, patient responses to the chemotherapy, and antitumor drugs could be clearly demonstrated.